Use of HMG-CoA reductase inhibitors after kidney and heart transplantation: Lipid-lowering and immunosuppressive effects

BioDrugs

Volumn 8, Issue 5, 1997, Pages 387-393

  Wanner, Christoph ^a,b   Krämer Guth, Annette ^a   Galle, Jan ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Department of Medicine   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CYCLOSPORIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DRUG POTENTIATION; DYSLIPIDEMIA; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; TREATMENT OUTCOME; VASCULAR DISEASE;

EID: 0030669161     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-199708050-00006     Document Type: Review

References (53)

1. Dimeny E, Tuveson G, Lithell H, et al. The influence of pretransplant lipoprotein abnormalities on the early results of renal transplantation. Eur J Clin Invest 1993; 23: 572-9
2. Kasiske BL, Tortorice KL, Heim-Duthoy KL, et al. The adverse impact of cyclosporine on serum lipids in renal transplant recipients. Am J Kidney Dis 1991; 17: 700-7
3. Cassader M, Ruiu G, Gambino R, et al. Lipoprotein-apolipoprotein changes in renal transplant recipients: a 2-year follow-up. Metabolism 1991; 40: 922-5
4. Kasiske BL, Umen AJ. Persistent hyperlipidemia in renal transplant recipients. Medicine 1987; 66: 309-16
5. Hricik DE, Mayes JT, Schulak JA. Independent effects of cyclosporine and prednisolone on posttransplant hypercholesterolemia Am J Kidney Dis 1991; 18: 353-8
6. Ballantyne CM, Podet EJ, Patsch WP, et al. Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA 1989; 262: 53-6
7. Jackson JM, Lee HA. The role of propranolol therapy and proleinuria in the etiology of post renal transplantation hyperlipidemia. Clin Nephrol 1982; 18: 95-100
8. Versluis DJ, Wenting GJ, Weimar W, Alterations in lipid and carbohydrate metabolism attributable to cyclosporin A in renal transplant recipients [letter]. BMJ 1987; 292: 272
9. Derfler K, Hayde M, Heinz G, et al. Decreased postheparin lipolytic activity in renal transplant recipients with cyclosporin A. Kidney Int 1991; 40: 720-6
10. Brown JH, Anwar N, Short CD et al. Serum lipoprotein(a) in renal transplant recipients receiving cyclosporin monotherapy. Nephrol Dial Transplant 1993; 8: 863-7
11. Eich D, Thompson JA, Ko DJ, et al. Hypercholesterolemia in long-term survivors of heart transplantation: an early marker of accelerated coronary artery disease. J Heart Lung Transplant 1991; 10: 45-9
12. Raine AEG. Hypertension and ischaemic heart disease in renal transplant recipients. Nephrol Dial Transplant 1995; 10 Suppl. 1: 95-100
13. Abdulmassih Z, Chevalier A, Bader C, et al. Role of lipid disturbances in the atherosclerosis of renal transplant patients. Clin Transplant 1992; 6: 106-13
14. Vathsala A, Weinberg RB, Schoenberg L, et al. Lipid abnormalities in cyclosporine-prednisolone-treated renal transplant recipients. Transplantation 1989; 48: 37-43
15. Wanner C, Bartens W, Galle J. Clinical utility of antilipidemic therapies in chronic renal allograft failure. Kidney Int 1995; 48 Suppl. 52: 60-2
16. Henwood JM, Heel RC. Lovastatin: a preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia. Drugs 1988; 36: 429-54
17. Vyas KP, Kari PH, Pithenberger SM, et al. Biotransformation of lovastatin. I. Structure elucidation of in vitro and in vivo metabolites in rat and mouse. Drug Metab Dispos 1990; 18: 203-11
18. Duggan DE, Chen IW, Bayne WF et al. The physiological disposition of lovastatin. Drug Metab Dispos 1989; 17: 166-73
19. Wang RW, Kari PH, Lu AYH, et al. Biotransfomiation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for oxidative metabolism of lovastatin in rat and human liver microsomes. Arch Biochem Biophys 1991; 280: 355-61
20. Amadottir M, Eriksson L-O, Thysell H, et al. Plasma concentration profiles of simvastatin 3-hydroxy-3-methylglularyl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. Nephron 1993; 65: 410-3
21. Kliem V, Wanner C Eisenhauer T, et al. Comparison of pravastatin and lovastatin in renal transplant patients receiving cyclosporine. Transplant Proc 1996; 28: 3126-28
22. Quion JAV, Jones PH. Clinical pharmacokinetics of pravastatin. Clin Pharmacokinet 1994; 27: 94-193
23. Appel S, Dingemanse J. Pharmacokinetic and pharmacodynamic interactions of fluvastatin and their therapeutic implications. Rev Contemp Pharmacother 1996; 7: 167-82
24. Singhvi SM, Pan HY, Morrison RA et al. Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. Br J Clin Pharmacol 1990; 29: 239-43
25. Vyas KP, Kari PH, Wang RW et al. Biotransformation of lovastatin. III. Effect of cimetidine and famotidine on in vitro metabolism by rat and human liver microsomes. Biochem Pharmacol 1988; 39: 67-73
26. Tse FLD, Jaffe JM, Troendle A. Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. J Clin Pharmacol 1992; 32: 630-8
27. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival study (4S). Lancet 1994; 344: 1765-9
28. Shepherd J, Cobbe SM, Ford I, et al., West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7
29. Pyörälä K, De Backer G, Graham I, et al. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology. European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994; 15: 1300-31
30. National Cholesterol Education Program Expert Panel. Report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. Arch Intern Med 1988; 148: 36-69
31. Kobashigawa JA, Katznelson S. Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621-27
32. Katznelson S, Wilkinson AH, Kobashigawa JA, et al. The effect of pravastatin on acute rejection after kidney transplantation; a pilot study. Transplantation 1996; 61: 1469-74
33. DeGroen PC. Cyclosporine. low-density lipoprotein. and cholesterol. Mayo Clin Proc 1988; 63: 1012-21
34. Cutts JL, Bankurst AD. Suppression of lymphoid cell function in vitro by inhibition of 3-hydroxy-3-methylglutaryl enzyme A reductase by lovastatin. Int J Immunopharmacol 1989; 11: 863-9
35. Kreuzer J, Bader J. Jahn L, et al. Chemotaxis of the monocyte line U937: dependence on cholesterol and early mevalonate pathway products. Atherosclerosis 1991; 90: 203-7
36. Cutts JL, Bankhurst AD. Reversal of lovastatin-mediated inhibition of natural killer cell cytotoxicily by interleukin 2. J Cell Physiol 1990; 145: 244-50
37. Kirby JA, Givan AL, Sheton BK, et al. Renal allograft rejection: possible involvement of antibody-dependent cell-mediated cytotoxicity. Transplantation 1990; 50: 225-30
38. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990; 343: 425-30
39. Dimeny E, Wahlberg J, Lithell H, et al. Hyperlipidaemia in renal transplantation: a risk factor for long-term graft outcome. Eur J Clin Invest 1995; 25: 574-83
40. Kasiske BL, Guijarro C, Massy ZA, et al. Cardiovascular disease after renal transplantation. J Am Soc Nephrol 1996; 7: 158-65
41. Massy ZA, Ma JZ, Louis TA, et al. Lipid-lowering therapy in patients with renal disease. Kidney Int 1995; 48: 188-98
42. Pichard L, Fahre I, Fahre G, et al., Cyclosporin A drug interactions: screening for inducers and inhibitors of cytochrome P-450 (cyclosporine A oxidase) in primary cultures of human hepalocytes and in liver microsomes. Drug Metab Dispos 1990; 18: 595-606
43. East C, Alivizatas PA, Grundy SM, et al. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. N Engl J Med 1988; 318: 47-8
44. Holdaas H, Hartmann A, Stenstrom J, et al. Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine. Am J Cardiol 1995; 76: 102A-6A
45. Biesenbach G, Janko O, Stuby U, et al. Myoglobinuric renal failure due to long-standing therapy in a patient with preexisting chronic renal insufficiency. Nephrol Dial Transpl 1996; 11: 2059-60
46. Kobashigawa JA, Murphy FL, Stevenson LW, et al. Low-dose lovastatin safely lowers cholesterol after cardiac transplantation. Circulation 1990; 82: 281-3
47. Martinez-Hernandez BE. Persaud JW, Varghese Z, et al. Low-dose simvastatin is safe in hyperlipidaemic renal transplant patients. Nephrol Dial Transplant 1993; 8: 637-41
48. Arnadottir M, Eriksson L-O, Germershausen JI, et al. Low-dose simvastatin is a well tolerated and efficacious cholesterol-lowering agent in ciclosporine-treated kidney transplant recipients: double-blind, randomized placebo-controlled study in 40 patients. Nephron 1994; 68: 57-62
49. Barbir M, Rose M, Kushwaha S, et al. Low dose simvastatin for the treatment of hypercholesterolaemia in recipients of cardiac transplantation. Int J Cardiol 1991; 33: 241-6
50. Yoshimura N, Oka T, Okamoto M, et al. The effects of pravastatin on hyperlipidemia in renal transplant recipients. Transplantation 1993; 53: 94-9
51. Lye WC, Hughes K, Leong SO, et al. Abnormal lipoprotein (a) and lipid profiles in renal allograft recipients: effects of treatment with pravastatin. Transplant Proc 1995; 27: 977-8
52. Goldberg RB, Roth D. A preliminary report of the safety and efficacy of fluvastatin for hypercholesterolemia in renal transplant patients receiving cyclosporine. Am J Cardiol 1995; 76: 107A-9A
53. Ghods AJ, Milanian I, Arghani H, et al. The efficacy and safety of fluvastatin in hypercholesterolemia in renal transplant recipients. Transplant Proc 1995; 27: 2579-80